Other Events ·
At its 2026 Annual Meeting of Shareholders held on June 22, 2026, UroGen Pharma Ltd. shareholders approved several key…
URGNUroGen Pharma Ltd.
At its 2026 Annual Meeting of Shareholders held on June 22, 2026, UroGen Pharma Ltd. shareholders approved several key proposals. These included the amendment and restatement of the company's Articles of Association to align shareholder proposal eligibility with Israeli Companies Law, an amendment to the Non-Employee Director and Officer Compensation Policy regarding insurance, and an amendment to the 2017 Equity Incentive Plan to increase authorized ordinary shares by 1,000,000. Additionally, shareholders elected seven directors, approved advisory say-on-pay, and ratified PricewaterhouseCoopers LLP as the independent auditor. UroGen Pharma Ltd. is a biopharmaceutical company focused on developing therapies for urological diseases.